Loading
NASDAQHealthcareMedical - Healthcare Plans
Latest quote
$27.785
+$0.235 · +0.85%
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Regular session
$27.8573
+$0.3073 · +1.12%
Regular session · ET · Market data may be delayed.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Day range
Current $27.8573
52-week range
Current $27.8573
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
77
Undervalued
Sentiment
60
Mixed
Risk
25
Moderate Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Day range
Current $27.8573
52-week range
Current $27.8573
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.29B USD | 1.17B USD | 1.09B USD | 786.91M USD | 500.62M USD |
| Cost of goods sold | 984.18M USD | 913.86M USD | 849.8M USD | 619.59M USD | 388.49M USD |
| Gross profit | 304.48M USD | 253.36M USD | 238.8M USD | 167.33M USD | 112.14M USD |
| Selling, general, and administrative | 219.21M USD | 185.91M USD | 176.62M USD | 143.98M USD | 79.8M USD |
| Operating expenses | 219.21M USD | 185.91M USD | 176.62M USD | 143.98M USD | 79.8M USD |
| Interest income | 10.16M USD | 15.75M USD | 8.51M USD | 814K USD | 461K USD |
| Depreciation and amortization | 4.95M USD | 3.18M USD | 2.28M USD | 1.6M USD | 1.3M USD |
| Operating income | 85.28M USD | 67.46M USD | 62.18M USD | 23.34M USD | 32.34M USD |
| Net income | 58.52M USD | 54.34M USD | 62.04M USD | 30.36M USD | 65.77M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$35.50
27.44% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
